Fecal microbiota transplantation as a treatment option for patients with recurrent Clostridioides difficile-associated diarrhea | CMAC

Fecal microbiota transplantation as a treatment option for patients with recurrent Clostridioides difficile-associated diarrhea

Clinical Microbiology and Antimicrobial Chemotherapy. 2022; 24(4):308-313

​ Ortenberg E.A.
10.36488/cmac.2022.4.308-313
Clostridioides difficile antibiotic-associated diarrhea pseudomembranous colitis treatment fecal microbiota transplantation
Section
Diseases and Pathogens
Type
Review
Publication
Clinical Microbiology and Antimicrobial Chemotherapy. 2022; 24(4):308-313

Abstract

This paper provides a review of the largest studies (over the period of 2017 to 2022) on the use of fecal microbiota transplantation (FMT) for the treatment of patients with recurrent *Clostridioides difficile*associated diarrhea (CDAD), including pseudomembranous colitis. A focus was made on methods of preparation and administration of fecal microbiota product. The recent systematic reviews and metaanalyses consistently consider TFM as an effective treatment option for recurrent CDAD. The different methods of fecal microbiota preparation and administration (fresh, frozen, lyophilized) show similar efficacy but differ by convenience of use.

Eduard A. Ortenberg

Tyumen State Medical University, Tyumen, Russia

  • 1. Taggart M.G., Snelling W.J., Naughton P.J., La Ragione R.M., Dooley J.S.G., Ternan N.G. Biofilm regulation in Clostridioides difficile: novel systems linked to hypervirulence. PLoS Pathog. 2021;17(9):e1009817. DOI: 10.1371/journal.ppat.1009817
  • 2. Granata G., Petrosillo N., Moghazi S.A., Taglietti F., Petrosillo N. The burden of Clostridioides difficile infection in COVID-19 patients: a systematic review and metaanalysis. Anaerobe. 2022;74:102484. DOI: 10.1016/j.anaerobe.2021.102484
  • 3. Bowman J.A., Utter G.H. Evolving strategies to manage Clostridium difficile colitis. J Gastrointest Surg. 2020; 24(2):484-491. DOI: 10.1007/s11605-019-04478-5
  • 4. Gupta A., Ananthakrishnan A.N. Economic burden and cost-effectiveness of therapies for Clostridiodes difficile infection: a narrative review. Therap Adv Gastroenterol. 2021;14:17562848211018654. DOI: 10.1177/17562848211018654
  • 5. Kampouri E., Croxatto A., Prod’hom G., Guery B. Clostridioides difficile infection, still a long way to go. J Clin Med. 2021;10(3):389. DOI: 10.3390/jcm10030389
  • 6. van Nood E.,Vrieze A., Nieuwdorp M., Fuentes S., Zoetendal E.G., de Vos W.M., et al. Duodenal infusion of donor feces for recurrent Clostridium difficile. N Engl J Med. 2013;368(5):407-415. DOI: 10.1056/NEJMoa1205037
  • 7. Quraishi M.N., Widlak M., Bhala N., Moore D., Price M., Sharma N., Iqbal T.H. Systematic review with meta-analysis: the efficacy of fecal microbiota transplantation for the treatment of recurrent and refractory Clostridium difficile infection. Aliment Pharmacol Ther. 2017;46(5):479-493. DOI: 10.1111/apt.14201
  • 8. Cammarota G., Ianiro G., Tilg H., Rajilić-Stojanović M., Kump P., Satokari R., et al. European consensus conference on faecal microbiota transplantation in clinical practice. Gut. 2017;66(4):569-580. DOI: 10.1136/gutjnl-2016-313017
  • 9. Fischer M., Sipe B., Cheng Y., Phelps E., Rogers N., Sagi S., et al. Fecal microbiota transplant in severe and severe-complicated Clostridium difficile: a promising treatment approach. Gut Microbes. 2017;8(3):289-302. DOI: 10.1080/19490976.2016.1273998
  • 10. Tixier E.N., Verheyen E., Luo Y., Grinspan L.T., Du C.H., Ungaro R.C., et al. Systematic review with meta-analysis: fecal microbiota transplantation for severe or fulminant Clostridioides difficile. Dig Dis Sci. 2022;67(3):978-988. DOI: 10.1007/s10620-021-06908-4
  • 11. Song Y.N., Yang D.Y., Veldhuyzen van Zanten S., Wong K., McArthur E., Song C.Z., et al. Fecal microbiota transplantation for severe or fulminant Clostridioides difficile infection: systematic review and meta-analysis. J Can Assoc Gastroenterol. 2021;5(1):e1-e11. DOI: 10.1093/jcag/gwab023
  • 12. McDonald L.C., Gerding D.N., Johnson S., Bakken J.S., Carroll K.C., Coffin S.E., et al. Clinical practice guidelines for Clostridium difficile infection in adults and children: 2017 update by the Infectious Diseases Society of America (IDSA) and Society for Healthcare Epidemiology of America (SHEA). Clin Infect Dis. 2018;66(7):e1-e48. DOI: 10.1093/cid/cix1085
  • 13. van Prehn J., Reigadas E., Vogelzang E.H., Bouza E., Hristea A., Guery B., et al. European Society of Clinical Microbiology and Infectious Diseases: 2021 update on the treatment guidance document for Clostridioides difficile infection in adults. Clin Microbiol Infect. 2021;27(Suppl. 2):S1-S21. DOI: 10.1016/j.cmi.2021.09.038
  • 14. Rajasingham R., Enns E.A., Khoruts A., Vaughn B.P. Costeffectiveness of treatment regimens for Clostridioides difficile infection: an evaluation of the 2018 Infectious Diseases Society of America guidelines. Clin Infect Dis. 2020;70(5):754-762. DOI: 10.1093/cid/ciz318
  • 15. Le P., Nghiem V.T., Mullen P.D., Deshpande A. Costeffectiveness of competing treatment strategies for Clostridium difficile infection: a systematic review. Infect Control Hosp Epidemiol. 2018;39(4):412-424. DOI: 10.1017/ice.2017.303
  • 16. Sandhu A., Chopra T. Fecal microbiota transplantation for recurrent Clostridioides difficile, safety, and pitfalls. Therap Adv Gastroenterol. 2021;14:17562848211053105. DOI: 10.1177/17562848211053105
  • 17. Kelly C.R., Yen E.F., Grinspan A.M., Kahn S.A., Atreja A., Lewis J.D., et al. Fecal microbiota transplantation is highly effective in real-world practice: initial results from the FMT National Registry. Gastroenterology. 2021;160(1):183192.e3. DOI: 10.1053/j.gastro.2020.09.038
  • 18. Hammeken L.H., Baunwall S.M., Hvas C.L., Ehlers L.H. Health economic evaluations comparing faecal microbiota transplantation with antibiotics for treatment of recurrent Clostridioides difficile infection: a systematic review. Health Econ Rev. 2021;11(1):3. DOI: 10.1186/s13561021-00301-7
  • 19. Youngster I., Russell G.H., Pindar C., Ziv-Baran T., Sauk J., Hohmann E.L. Oral, capsulized, frozen fecal microbiota transplantation for relapsing Clostridium difficile infection. JAMA. 2014;312(17):1772-1778. DOI: 10.1001/jama.2014.13875
  • 20. Jiang Z.D., Ajami N.J., Petrosino J.F., Jun G., Hanis C.L., Shah M., et al. Randomised clinical trial: faecal microbiota transplantation for recurrent Clostridum difficile infection – fresh, or frozen, or lyophilised microbiota from a small pool of healthy donors delivered by colonoscopy. Aliment Pharmacol Ther. 2017;45(7):899-908. DOI: 10.1111/apt.13969
  • 21. Jiang Z.D., Jenq R.R., Ajami N.J., Petrosino J.F., Alexander A.A., Ke S., et al. Safety and preliminary efficacy of orally administered lyophilized fecal microbiota product compared with frozen product given by enema for recurrent Clostridium difficile infection: a randomized clinical trial. PLoS One. 2018;13(11):e0205064. DOI: 10.1371/journal.pone.0205064
  • 22. Hecker M.T., Obrenovich M.E., Cadnum J.L., Jencson A.L., Jain A.K., Ho E., Donskey C.J. Fecal microbiota transplantation by freeze-dried oral capsules for recurrent Clostridium difficile infection. Open Forum Infect Dis. 2016;3(2):ofw091. DOI: 10.1093/ofid/ofw091
  • 23. Kao D., Roach B., Silva M., Beck P., Rioux K., Kaplan G.G., et al. Effect of oral capsule- vs colonoscopy-delivered fecal microbiota transplantation on recurrent Clostridium difficile infection. JAMA. 2017;318(20):1985-1993. DOI: 10.1001/jama.2017.17077
  • 24. Ramai D., Zakhia K., Fields P.J., Ofosu A., Patel G., Shahnazarian V., et al. Fecal microbiota transplantation (FMT) with colonoscopy is superior to enema and nasogastric tube while comparable to capsule for the treatment of recurrent Clostridioides difficile infection: a systematic review and meta-analysis. Dig Dis Sci. 2021;66(2):369380. DOI: 10.1007/s10620-020-06185-7
  • 25. Ianiro G., Maida M., Burisch J., Simonelli C., Hold G., Ventimiglia M., et al. Efficacy of different faecal microbiota transplantation protocols for Clostridium difficile infection: a systematic review and meta-analysis. United European Gastroenterol J. 2018;6(8):1232-1244. DOI: 10.1177/2050640618780762
  • 26. Stallmach A., Steube A., Grunert P., Hartmann M., Biehl L.M., Vehreschild M.J.G.T. Fecal microbiota transfer. Dtsch Arztebl Int. 2020;117(3):31-38. DOI: 10.3238/arztebl.2020.0031
  • 27. Ng S.C., Kamm M.A., Yeoh Y.K., Chan P.K.S., Zuo T., Tang W., et al. Scientific frontiers in faecal microbiota transplantation: joint document of Asia-Pacific Association of Gastroenterology (APAGE) and Asia-Pacific Society for Digestive Endoscopy (APSDE). Gut. 2020;69(1):83-91. DOI: 10.1136/gutjnl-2019-319407
  • 28. Baunwall S.M, Lee M., Eriksen M., Mullish B.H., Marchesi J.R., Dahlerup J.F., Hvas C.L. Faecal microbiota transplantation for recurrent Clostridioides difficile infection: an updated systematic review and metaanalysis. EClinicalMedicine. 2020;29-30:100642. DOI: 10.1016/j.eclinm.2020.100642
  • 29. Cold F., Baunwall S.M., Dahlerup J.F., Petersen A.M., Hvas C.L., Hansen L.H. Systematic review with metaanalysis: encapsulated faecal microbiota transplantation – evidence for clinical efficacy. Therap Adv Gastroenterol. 2021;14:17562848211041004. DOI: 10.1177/17562848211041004
  • 30. Nicco C., Paule A., Konturek P., Edeas M. From donor to patient: collection, preparation and cryopreservation of fecal samples for fecal microbiota transplantation. Diseases. 2020;8(2):9. DOI: 10.3390/diseases8020009
  • 31. Staley C., Hamilton M.J., Vaughn B.P., Graiziger C.T., Newman K.M., Kabage A.J., et al. Successful resolution of recurrent Clostridium difficile infection using freeze-dried, encapsulated fecal microbiota; pragmatic cohort study. Am J Gastroenterol. 2017;112(6):940-947. DOI: 10.1038/ajg.2017.6
  • 32. Reigadas E., Bouza E., Olmedo M., Vázquez-Cuesta S., Villar-Gómara L., Alcalá L., et al. Faecal microbiota transplantation for recurrent Clostridioides difficile infection: experience with lyophilized oral capsules. J Hosp Infect. 2020;105(2):319-324. DOI: 10.1016/j.jhin.2019.12.022
  • 33. Halaweish H.F., Boatman S., Staley C. Encapsulated fecal microbiota transplantation: development, efficacy, and clinical application. Front Cell Infect Microbiol. 2022;12:826114. DOI: 10.3389/fcimb.2022.826114
  • 34. Haifer C., Paramsothy S., Borody T.J., Clancy A., Leong R.W., Kaakoush N.O., et al. Long-term bacterial and fungal dynamics following oral lyophilized fecal microbiota transplantation in Clostridioides difficile infection. mSystems. 2021;6(1):e00905-20. DOI: 10.1128/mSystems.00905-20
  • 35. Gweon T., Lee Y.J., Kim K.O., Yim S.K., Soh J.S., Kim S.Y., et al. Clinical practice guidelines for fecal microbiota transplantation in Korea. J Neurogastroenterol Motil. 2022;28(1):28-42. DOI: 10.5056/jnm21221
  • 36. Cammarota G., Ianiro G., Kelly C.R., Mullish B.H., Allegretti J.R., Kassam Z., et al. International consensus conference on stool banking for faecal microbiota transplantation in clinical practice. Gut. 2019;68(12):21112121. DOI: 10.1136/gutjnl-2019-319548
  • 37. Terveer E.M., Vendrik K.E., Ooijevaar R.E., Lingen E.V., Boeije-Koppenol E., Nood E.V., et al. Faecal microbiota transplantation for Clostridioides difficile infection: four years’ experience of the Netherlands Donor Feces Bank. United European Gastroenterol J. 2020;8(10):12361247. DOI: 10.1177/2050640620957765
Views
0 Abstract
0 PDF
0 Crossref citations
Shared